Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies-Reference-Cited by-同舟云学术

Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

Published:2021-11-12 Issue: Volume: Page:
ISSN:0007-9235
Container-title:CA: A Cancer Journal for Clinicians
language:en
Short-container-title:CA A Cancer J Clin

Author:

Tarantino Paolo¹²,Carmagnani Pestana Roberto³,Corti Chiara¹²,Modi Shanu⁴,Bardia Aditya⁵⁶,Tolaney Sara M.⁵⁷,Cortes Javier⁸⁹¹⁰¹¹^ORCID,Soria Jean‐Charles¹²¹³,Curigliano Giuseppe¹²^ORCID

Affiliation:

1. Division of New Drugs and Early Drug Development European Institute of Oncology IRCCS Milan Italy

2. Department of Oncology and Hemato‐Oncology University of Milan Milan Italy

3. Dayan‐Daycoval Family Center for Oncology and Hematology Albert Einstein Israelite Hospital Sao Paulo Brazil

4. Breast Medicine Service Memorial Sloan Kettering Cancer CenterWeill Cornell Medical College New York New York

5. Harvard Medical School Boston Massachusetts

6. Breast Cancer Treatment Program Massachusetts General Hospital Boston Massachusetts

7. Dana‐Farber Cancer Institute Boston Massachusetts

8. International Breast Cancer Center, Quironsalud Group Barcelona Spain

9. Medica Scientia Innovation Research Barcelona Spain

10. Vall d'Hebron Institute of Oncology Barcelona Spain

11. Faculty of Biomedical and Health Sciences Department of Medicine European University of Madrid Madrid Spain

12. Paris Saclay University St Aubin France

13. Drug Development Department Gustave Roussy Villejuif France

Publisher

Wiley

Subject

Oncology,Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.3322/caac.21705

Reference125 articles.

1. Two Hundred Years of Cancer Research

2. Cancer immunotherapy comes of age

3. The paradox of precision medicine

4. Histology-agnostic drug development — considering issues beyond the tissue

5. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

Cited by 192 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer;European Journal of Cancer;2024-10

2. Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2;Pathology - Research and Practice;2024-10

3. Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer;Biomedicine & Pharmacotherapy;2024-10

4. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance;Nature Reviews Clinical Oncology;2024-09-13

5. Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer;Cancers;2024-09-04